Walter H Koch
Overview
Explore the profile of Walter H Koch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
578
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sundaresan T, Sequist L, Heymach J, Riely G, Janne P, Koch W, et al.
Clin Cancer Res
. 2015 Oct;
22(5):1103-10.
PMID: 26446944
Purpose: The T790M gatekeeper mutation in the EGFR is acquired by some EGFR-mutant non-small cell lung cancers (NSCLC) as they become resistant to selective tyrosine kinase inhibitors (TKI). As third-generation...
2.
Cheng S, Koch W, Wu L
N Biotechnol
. 2012 Mar;
29(6):682-8.
PMID: 22391147
Oncology drug development is a long and costly process associated with a success rate of 5-10%. The parallel development of companion diagnostic tests that will identify patients most likely to...
3.
Wu L, Williams P, Koch W
Biotechniques
. 2005 Oct;
39(4):577-82.
PMID: 16235572
Nearly 15 years have passed since the possibility of analyzing nucleic acid analytes in a massively parallel fashion was proposed using the then new concept of microarrays. A decade ago,...
4.
Baker S, Bauer S, Beyer R, Brenton J, Bromley B, Burrill J, et al.
Nat Methods
. 2005 Sep;
2(10):731-4.
PMID: 16179916
Standard controls and best practice guidelines advance acceptance of data from research, preclinical and clinical laboratories by providing a means for evaluating data quality. The External RNA Controls Consortium (ERCC)...
5.
De Leon J, Susce M, Pan R, Koch W, Wedlund P
J Clin Psychopharmacol
. 2005 Sep;
25(5):448-56.
PMID: 16160620
This study tested the association between tardive dyskinesia (TD) and polymorphic variations in (a) 2 cytochrome P450 (CYP) genes (CYP2D6 or CYP3A5), (b) 2 DRD2 variants (Ser311Cys and -141C Ins/del)...
6.
7.
Candiotti K, Birnbach D, Lubarsky D, Nhuch F, Kamat A, Koch W, et al.
Anesthesiology
. 2005 Feb;
102(3):543-9.
PMID: 15731591
Background: Some patients treated with ondansetron for postoperative nausea and vomiting do not respond to therapy. One possible mechanism for this failure is ultrarapid drug metabolism via the cytochrome P-450...
8.
De Leon J, Susce M, Pan R, Fairchild M, Koch W, Wedlund P
J Clin Psychiatry
. 2005 Jan;
66(1):15-27.
PMID: 15669884
Objective: The cytochrome P450 2D6 (CYP2D6) enzyme metabolizes risperidone. CYP2D6 poor metabolizers have no CYP2D6 activity (7% of whites and 1%-2% of other races). This study tested whether the CYP2D6...
9.
Koch W
Nat Rev Drug Discov
. 2004 Sep;
3(9):749-61.
PMID: 15340385
Rapid advances in the understanding of genomic variation affecting drug responses, and the development of multiplex assay technologies, are converging to form the basis for new in vitro diagnostic assays....
10.
Chou W, Yan F, Robbins-Weilert D, Ryder T, Liu W, Perbost C, et al.
Clin Chem
. 2003 Mar;
49(4):542-51.
PMID: 12651805
Background: There have been no published reports comparing the CYP450 GeneChip microarray assay with more standard methods of genetic testing. Methods: We collected 20-mL blood samples from 236 volunteers for...